pirfenidone has been researched along with Necrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaibori, M; Kamiyama, Y; Kwon, AH; Okumura, T; Tsuchiya, H; Yanagida, H; Yokoigawa, N | 1 |
| Horikawa, T; Nakazato, H; Oku, H; Suzuki, R; Tsuruta, Y | 1 |
2 other study(ies) available for pirfenidone and Necrosis
| Article | Year |
|---|---|
Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats.
Topics: Animals; Chemokines, CXC; Cytokines; Endotoxemia; Hepatectomy; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Liver; Liver Diseases; Male; Necrosis; Neutrophil Infiltration; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pyridones; Rats; Rats, Sprague-Dawley; Survival Rate; Transcription Factors | 2004 |
Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Galactosamine; Interferon-gamma; Interleukin-10; Interleukin-12; Lipopolysaccharides; Liver; Liver Failure; Mice; Mice, Inbred C57BL; Necrosis; Pyridones; Shock, Septic; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2002 |